Article thumbnail

Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy

By Wenxue Ma, Trevor Smith, Vladimir Bogin, Yu Zhang, Cengiz Ozkan, Mihri Ozkan, Melanie Hayden, Stephanie Schroter, Ewa Carrier, Davorka Messmer, Vipin Kumar and Boris Minev
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3078865
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). A balanced review of the status T cell-based therapy against cancer.
  2. (1997). A: Regulatory T cells specific for the same framework 3 region of the Vbeta8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis. J Exp Med
  3. (2007). Anti-TCR antibody treatment activates a novel population of nonintestinal CD8 alpha alpha+ TCR alpha beta+ regulatory T cells and prevents experimental autoimmune encephalomyelitis.
  4. Antonarakis ES: Update: immunological strategies for prostate cancer.
  5. (2005). Avigan D: Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther
  6. (2007). Baxevanis CN: Ii-Key/HER-2/neu (776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother
  7. (2003). Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target
  8. (2005). Borrebaeck CA: Nanosphere induced gene expression in human dendritic cells. Nano Lett
  9. (2002). Characterization of nanoparticle uptake by endothelial cells.
  10. (2004). Characterization of poly(D, Llactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine
  11. (2003). Crommelin DJ: Liposomes and ISCOMs. Vaccine
  12. (2001). ES: Induction of a type 1 regulatory CD4 T cell response following V beta 8.2 DNA vaccination results in immune deviation and protection from experimental autoimmune encephalomyelitis. Int Immunol
  13. (2001). Gene therapy. Safer and virus-free? Science
  14. (2004). Homeostatic control of immunity by TCR peptide-specific Tregs.
  15. (1999). Human tumor antigens: implications for cancer vaccine development.
  16. (2005). I: Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation.
  17. (2006). I: Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv
  18. (1986). Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid.
  19. (2006). JG: Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood
  20. (2003). JP: Physico-chemical stability of colloidal lipid particles. Biomaterials
  21. (2008). Kumar V: Revival of CD8+ Treg-mediated suppression. Trends Immunol
  22. (2004). Labhasetwar V: Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer.
  23. (2007). Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes.
  24. (2000). MS: Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1.
  25. (2009). Noske D: Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett
  26. (2004). Palucka AK: Autoimmunity through cytokineinduced dendritic cell activation. Immunity
  27. (1985). Patte D: Carbon-PGLA prostheses for ligament reconstruction. Experimental basis and short-term results in man. Clin Orthop Relat Res
  28. (2006). Regulation of immunity by a novel population of Qa1-restricted CD8alphaalpha+TCRalphabeta+ T cells.
  29. (2003). Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes.
  30. (1994). Restifo NP: Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma- bearing mice. Cancer Res
  31. (2006). Riccobon A: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients.
  32. (1992). RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor.
  33. (1995). Rock KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science
  34. (2003). S: HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol
  35. (1993). Sercarz EE: The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease.
  36. (1998). SY: Preparation of chitosan selfaggregates as a gene delivery system. J Control Release
  37. (2007). Taking dendritic cells into medicine. Nature
  38. (1985). Tamminmaki M: Biodegradable implants in fracture fixation: early results of treatment of fractures of the ankle. Lancet
  39. (2004). The second annual symposium on nanomedicine and drug delivery: exploring recent developments and assessing major advances.
  40. (2007). Wiertz EJ: The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. J Immunol
  41. (2001). Zinkernagel RM: Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells.
  42. (2005). Zitvogel L: Dendritic cell-derived exosomes as cell-free peptide-based vaccines. Crit Rev Immunol
  43. (2005). Zurbriggen R: Peptides delivered by immunostimulating reconstituted influenza virosomes.